Angiotensin II receptor antagonists: where do we stand?

Details

Serval ID
serval:BIB_30B1FBA2DEF6
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Angiotensin II receptor antagonists: where do we stand?
Journal
IDrugs
Author(s)
Burnier  M., Maillard  M.
ISSN
1369-7056 (Print)
Publication state
Published
Issued date
03/2000
Volume
3
Number
3
Pages
304-9
Notes
Journal Article --- Old month value: Mar
Abstract
Losartan, the first angiotensin II receptor antagonist was introduced in 1994. Since then, five other antagonists have been launched for the management of hypertension. In recent years, numerous studies have demonstrated that angiotensin II antagonists are as effective as other antihypertensive agents but with a better tolerability profile. The challenge with these agents is now to demonstrate their potential benefits on morbidity and mortality, and several very large clinical trials are therefore running in hypertension, congestive heart failure and diabetic nephropathy. In addition, research is focusing intensively on defining the role of angiotensin AT2 receptors, and the potential benefits of combining ACE inhibitors and angiotensin II antagonists.
Pubmed
Create date
25/01/2008 13:59
Last modification date
20/08/2019 14:15
Usage data